FDA Draft Guidance Extends Reprint Policy To Medical Reference Texts, Clinical Practice Guidelines
This article was originally published in The Gray Sheet
Executive Summary
FDA has revised, but not loosened, its 2009 policy on the practices manufacturers should follow when giving physicians reprints of journal articles and other publications that discuss unapproved uses of legally marketed medical devices and drugs.
You may also be interested in...
Off-Label Questions, Online: FDA Explains How To Handle Them
FDA draft guidance weighs in on web communications, saying that firms must answer off-label-information questions privately, even if the questions arise in a public online forum.
FDA Issues Guidance On Off-Label Info; Waxman Seeks ‘Re-examination’
Rep. Henry Waxman is calling for the Obama administration to re-examine a final FDA guidance that gives companies a way to distribute journal articles discussing off-label uses for approved medical devices and drugs
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.